We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Conduct Superiority Trials With PRO Endpoint for ABECB-COPD Drugs
FDA: Conduct Superiority Trials With PRO Endpoint for ABECB-COPD Drugs
October 10, 2012
Drugmakers should use superiority trials when developing antimicrobial drugs for the treatment of acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease (ABECB-COPD), according to an updated FDA guidance.